Project Title

A Phase 3 multicentre study comparing the efficacy and safety of IberDd versus DVd in participants with relapsed or refractory multiple myeloma (RRMM) - EXCALIBER

Official Title

A Phase 3, two-stage, randomised, multicentre, open-lable study comparing Iberdomide, Daratumumab and Dexamethsone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in subjects with relapsed or refractory multiple myeloma (RRMM) - EXCALIBER-RRMM

Project Summary

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Blood Disorder

  • Relapsed or refractory multiple myeloma

Patient Recruitment Details

Patient recruitment status: open for recruitment

Number of patients (Globally)

Undetermined.